Ozempic Injection, Solution
Product Images NDC 50090-6051

Product Visual Gallery

This gallery contains 100 technical images submitted to the FDA as part of the official labeling for Ozempic (NDC 50090-6051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ozempic_ifu_us_flow_symbol_1 (Export 00)

OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use. The label shows the product name OZEMPIC with its active ingredient semaglutide, strength 2.68 mg/mL, and manufacturer A-S Medication Solutions. The label design includes dosage form details and the product NDC 50090-6051.*

FDA Label Image

Structural Formula (Image 01)

Chemical structure diagram of semaglutide, the active ingredient in OZEMPIC 2.68 mg/mL subcutaneous injection. The diagram shows the peptide chain composition and the attached fatty acid moiety characteristic of semaglutide.*

FDA Label Image

Figure 1 (Image 02)

A line graph depicting plasma glucose levels (mg/dL) over 24 hours since the start of a breakfast meal. The graph compares four groups: OZEMPIC 0.5 mg, OZEMPIC 1 mg, placebo baseline, and placebo, showing glucose fluctuations across time intervals in hours.*

FDA Label Image

Figure 2 (Image 03)

A line graph showing insulin secretion rate (pmol/kg/min) plotted against plasma glucose levels (mg/dL). The graph compares multiple groups including baseline, subjects with CCI-IMF treatment and placebo, with separate lines for healthy subjects. Different markers and line styles represent each group across a plasma glucose range from 90 to 210 mg/dL.*

FDA Label Image

Figure 3 (Image 04)

A chart depicting relative exposure (Cavg) ratios and 90% confidence intervals for semaglutide by intrinsic factors including sex, age, race, ethnicity, body weight, and renal impairment. The chart shows the comparison of semaglutide exposure relative to a reference subject profile, illustrating variations across categories such as male vs. female, age groups, racial and ethnic groups, different body weights, and levels of renal impairment.*

FDA Label Image

Figure 4 (Image 05)

A chart titled 'Relative exposure Ratio and 90% CI' comparing the effects of various co-administered medications (Metformin, S-warfarin, R-warfarin, Digoxin, Atorvastatin, Ethinylestradiol, Levonorgestrel) on drug exposure. The chart shows relative exposure ratios around 1 with error bars, and a consistent recommendation of 'No dose adjustment' for all medications.*

FDA Label Image

Figure 5 (Image 06)

A line graph comparing the percentage of HbA1c over time (weeks post randomization) among three groups: OZEMPIC 0.5 mg, OZEMPIC 1 mg, and Sitagliptin. The x-axis shows weeks from 0 to 56, and the y-axis shows HbA1c percentage ranging approximately from 6.0% to 8.5%. The graph includes data points and a table listing the number of patients per group at various time points.*

FDA Label Image

Warning 1 (Image 07)

OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use in a prefilled pen. The label identifies the active ingredient semaglutide and the labeler A-S Medication Solutions. The image shows drug name, dosage strength, and usage instructions in black text on a yellow and white background.*

FDA Label Image

Device 1 (Image 08)

An instructional diagram of the OZEMPIC pen injection device and NovoFine Plus needle components. It labels parts of the pen including the pen cap, pen window, dose counter, dose pointer, dose selector, dose button, expiration date area, and features of the dose display such as the flow check symbol and dashed line. The needle assembly parts are also identified: outer needle cap, inner needle cap, needle, and paper tab.*

FDA Label Image

A (Image 09)

An instructional illustration showing hands manipulating a pen injector, likely demonstrating how to use or prepare the device for a subcutaneous injection. The image contains step-by-step visual guidance related to injection technique, consistent with patient usage instructions for an injectable drug like OZEMPIC (semaglutide).*

FDA Label Image

B (Image 10)

An instructional illustration showing a hand holding an injection pen device, likely for subcutaneous administration. The image focuses on the grip and preparation of the injection pen, without visible branding or text.*

FDA Label Image

Flow_symbol (Image 100)

OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use, displayed in a Vial with a purple cap. The label shows the brand name, dosage strength, and NDC 50090-6051, labeled by A-S Medication Solutions.*

FDA Label Image

Symbol (Image 101)

OZEMPIC 2.68 mg/mL injection solution label, a human prescription drug by A-S Medication Solutions. The label includes product name, generic name semaglutide, strength, dosage form as injection, and route of administration subcutaneous. It also displays the product NDC 50090-6051 and other regulatory and identification details.*

FDA Label Image

2 mg. Pen (Overview)

An instructional diagram of the OZEMPIC pen and NovoFine Plus needle components. It details parts of the OZEMPIC pen injector including the pen cap, pen window, dose counter, dose pointer, dose selector, and dose button. The needle assembly is shown with outer needle cap, inner needle cap, needle, and paper tab. Additional features such as expiration date location and a flow check symbol with a dashed line guide are also labeled.*

FDA Label Image

Step 1 (Fig. A)

An instructional illustration showing two hands pulling apart a device, likely demonstrating how to separate or prepare a component of the OZEMPIC injection pen for subcutaneous administration.*

FDA Label Image

Step 1 (Fig. B)

An illustration showing a close-up of a hand holding a syringe pen-style injector, highlighting the dosing window on the device. The image appears to be a step or guide in using the injection device for administering medication.*

FDA Label Image

Step 1 (Fig. C)

An instructional illustration showing a person's hand pulling off a protective cap from a pen-style injection device. The image focuses on the removal of the cap before use.*

FDA Label Image

Step 1 (Fig. D)

An instructional illustration showing a close-up of a hand turning or twisting the cap on the end of a pen-style injector device, likely demonstrating a step in preparing the OZEMPIC injection pen for use.*

FDA Label Image

Step 1 (Fig. E)

An instructional illustration showing a hand removing a cap from a needle on an injection pen device for OZEMPIC (semaglutide) injection, solution 2.68 mg/mL. The image emphasizes proper handling of the injection pen before subcutaneous administration.*

FDA Label Image

C (Image 11)

An instructional illustration showing a close-up of a hand preparing a subcutaneous injection using a pen device. The image depicts an arrow indicating the removal of a protective cap or needle cover from the pen, relevant to the administration of OZEMPIC (semaglutide) injection solution.*

FDA Label Image

Step 1 (Fig. F)

An instructional illustration showing a hand removing a cap from the needle of an injection pen, demonstrating preparation for subcutaneous injection.*

FDA Label Image

Step 2 (Fig. G)

An instructional illustration showing hands holding a blue injection pen with an arrow indicating a twisting motion. The image highlights selecting the flow check symbol on the dose display window, with a close-up inset showing the symbol clearly marked "mg." This depicts a step in preparing the OZEMPIC injection pen for use.*

FDA Label Image

Step 2 (Fiig. H)

An instructional illustration showing how to prepare a subcutaneous injection pen for use. The image depicts a hand holding an injection pen with a clear medication reservoir and a capped needle, accompanied by an arrow indicating the direction to pull the cap off.*

FDA Label Image

Step 3 (Fig. I)

An instructional illustration showing a hand adjusting the dose selector on an Ozempic injection pen for semaglutide 2.68 mg/mL. The image highlights selecting the 2 mg dose, with a dashed line indicator and a numbered dose window visible on the pen.*

FDA Label Image

Step 3 (Fig. J)

An instructional illustration showing a close-up of a dose counter on an Ozempic injection pen, indicating the remaining dose as 2 mg. The image includes a hand adjusting the dose knob and text noting "Dose counter stopped: 2 mg left." This visual helps users understand the dose adjustment mechanism for the semaglutide injection pen.*

FDA Label Image

Step 4 (Fig. K)

An instructional diagram showing a human figure from the front and back, highlighting recommended subcutaneous injection sites for the medication on the abdomen and both thighs.*

FDA Label Image

Step 4 (Fig. L)

An instructional illustration showing a hand holding a pen-like injector device vertically with the needle pointing downward, positioned for subcutaneous injection into the skin indicated by a downward arrow. The image likely demonstrates the proper injection technique for OZEMPIC (semaglutide) injection, solution, subcutaneous.*

FDA Label Image

Step 4 (Fig. M)

Instructional illustration showing a hand holding an injection pen device against the abdomen, with a downward arrow indicating the injection site. An inset shows a dosage dial set to zero milligrams, suggesting readiness for dose setting or injection preparation.*

FDA Label Image

Step 4 (Fig. N)

An instructional illustration showing a hand holding a pen-like injection device vertically with the needle pointing downward. A speech bubble instructs to count slowly from 1 to 6, indicating a timing step involved in the subcutaneous injection process.*

FDA Label Image

Step 4 (Fig. O)

An illustration showing a subcutaneous injection pen with an arrow pointing upward, likely indicating the direction to remove or attach a component before injection.*

FDA Label Image

D (Image 12)

An instructional diagram showing a hand holding and preparing an injection pen, likely for a subcutaneous injection. The image focuses on the pen device with a dial relative to the plunger mechanism, suggesting preparation or dose setting of the medication injection device.*

FDA Label Image

Step 5 (Fig. P)

An instructional illustration showing a hand gripping and rotating the cap of a prefilled injection pen, likely demonstrating preparation steps for subcutaneous administration.*

FDA Label Image

Step 5 (Fig. Q)

An instructional illustration showing the process of adding drops of liquid from a dropper bottle into a petri dish or similar round container, indicated by a large downward arrow directing the drops into the container’s center.*

FDA Label Image

Step 5 (Fig. R)

An instructional illustration showing hands peeling back the protective film from the cap of a device labeled with an 'R.' The image depicts the initial step in preparing the OZEMPIC (semaglutide) injection pen for use.*

FDA Label Image

Step 5 (Fig. S)

An instructional diagram showing the removal of a cap or cover from a pen-like medical device, with arrows indicating the direction to pull the cap away from the device. The background is light blue with a small 'S' icon in the top left corner.*

FDA Label Image

Warning Symbol (Image 124)

OZEMPIC 2.68 mg/mL injection solution for subcutaneous use in a prefilled pen device. The packaging displays branding details including the product name and strength prominently on a white and pink background. The labeler is A-S Medication Solutions, with NDC 50090-6051 shown on the carton.*

FDA Label Image

Warning Symbol (Image 125)

OZEMPIC 2.68 mg/mL solution for injection, a human prescription drug containing the active ingredient semaglutide. The label includes manufacturer information for A-S Medication Solutions and indicates the medication is for subcutaneous use. The product NDC is 50090-6051.*

FDA Label Image

Warning Symbol (Image 126)

OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use in a 1.5 mL cartridge for use with an injection device. The label displays the proprietary name OZEMPIC and the generic name semaglutide. The product is labeled by A-S Medication Solutions and includes the NDC 50090-6051. The cartridge is yellow-capped with graduation markings.*

FDA Label Image

Dashed Line (Image 127)

The image shows the label of OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use. The label includes the proprietary name OZEMPIC and the generic name semaglutide. It is labeled as a prescription human drug by A-S Medication Solutions with product NDC 50090-6051.*

FDA Label Image

Warning Symbol (Image 128)

The packaging label for OZEMPIC injection, solution, strength 2.68 mg/mL. It is a subcutaneous injection labeled for human prescription use. The label shows the product name OZEMPIC prominently, along with the generic name semaglutide, and indicates the labeler as A-S Medication Solutions.*

FDA Label Image

Warning Symbol (Image 129)

OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use in a pre-filled pen. The label includes the product name, active ingredient semaglutide, strength, route of administration, and manufacturer A-S Medication Solutions. The pen is designed for human prescription use and intended for subcutaneous injection.*

FDA Label Image

E (Image 13)

An instructional illustration depicting the preparation of a subcutaneous injection. It shows a hand holding a syringe and using a vial or pen device, indicating the step of attaching or drawing medication, relevant to injectable solutions like Ozempic (semaglutide).*

FDA Label Image

Warning Symbol (Image 130)

The packaging label shows OZEMPIC injection solution with semaglutide as the active ingredient in a strength of 2.68 mg/mL. The product is intended for subcutaneous use. The labeler is A-S Medication Solutions. The label features dosage instructions and handling information in a clear, text-based format on a white background with minimal graphics.*

FDA Label Image

Warning Symbol (Image 131)

OZEMPIC 2.68 mg/mL injection solution in a single-dose pen device. The carton shows the product name OZEMPIC with the active ingredient semaglutide. The labeler is A-S Medication Solutions. The image displays a white and purple box and a matching injection pen for subcutaneous use.*

FDA Label Image

Qr Code (Image 133)

FDA Label Image

F (Image 14)

An instructional illustration showing hands preparing a drug injection. It depicts the process of attaching a needle to a syringe or pen injector, indicated by an arrow guiding the step. This image is related to subcutaneous injection, relevant to the OZEMPIC injection solution.*

FDA Label Image

Warning 2 (Image 15)

The image shows the front label of OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use. The label includes the proprietary name OZEMPIC in large letters, mentions the concentration 2.68 mg/mL, and identifies semaglutide as the active ingredient. The labeler is A-S Medication Solutions. The packaging indicates it is a human prescription drug.*

FDA Label Image

Dose 1 (Image 16)

OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use in a pre-filled pen. The label includes the proprietary name OZEMPIC and the active ingredient semaglutide. The product is labeled by A-S Medication Solutions with NDC 50090-6051. The label also contains barcodes and usage instructions visible on the pen.*

FDA Label Image

G (Image 17)

An instructional diagram showing two hands holding a pen-like injection device. The illustration highlights the flow check symbol on the device with a label pointing to it, indicating where to check for proper flow before use.*

FDA Label Image

H (Image 18)

An instructional illustration showing a hand holding a semaglutide injection pen labeled OZEMPIC. The diagram depicts the pen with a cap being removed, indicated by an upward arrow, demonstrating how to prepare the injection device for subcutaneous use.*

FDA Label Image

Warning 3 (Image 19)

The image shows a carton of OZEMPIC injection, solution for subcutaneous use, containing semaglutide at a strength of 2.68 mg/mL. The packaging features the OZEMPIC brand name prominently, with active ingredient and strength indicated. The labeler is A-S Medication Solutions, and the box is designed for a prescription human drug product.*

FDA Label Image

Dash 1 (Image 20)

OZEMPIC 2.68 mg/mL injection solution for subcutaneous use in a prefilled pen injector. The label displays the product name, strength, dosage form, and the labeler A-S Medication Solutions. The pen is primarily white with orange and gray labeling details.*

FDA Label Image

I (Image 21)

An instructional diagram showing how to select the 1 mg dose on a semaglutide injection pen. The illustration highlights the pen dose selector turning until the dashed line aligns with the 1 mg dose marking, indicating the correct dose is selected.*

FDA Label Image

Warning 4 (Image 22)

OZEMPIC 2.68 mg/mL injection, solution in a 1.5 mL cartridge for subcutaneous use. The label specifies the A-S Medication Solutions as the labeler and includes the NDC 50090-6051. The cartridge is part of a pen-type delivery system with a visible dose window and safety cap.*

FDA Label Image

J (Image 23)

Instructional diagram showing a step to stop and remove the dose counter label on an Ozempic injection pen. The image highlights holding and pulling the dose counter sticker to complete the preparation of the pen for subcutaneous injection.*

FDA Label Image

K (Image 24)

An anatomical illustration showing front and back views of a human body with marked locations on the abdomen and thigh, likely indicating recommended injection sites for a subcutaneous medication.*

FDA Label Image

L (Image 25)

An instructional diagram showing a hand holding a pen-like injection device with the thumb pressing down on the plunger. A downward arrow indicates the direction of injection. The illustration is intended to guide proper use of the injection device for subcutaneous administration.*

FDA Label Image

M (Image 26)

Instructional illustration showing a hand holding an Ozempic injection pen with an arrow pointing downward, indicating the direction to press the injection button. This depicts the subcutaneous injection process for Ozempic (semaglutide) 2.68 mg/mL solution.*

FDA Label Image

N (Image 27)

An instructional illustration showing a hand holding a pen-like injection device. A speech bubble indicates counting slowly from 1 to 6, likely demonstrating the method to administer a subcutaneous injection dose carefully and steadily.*

FDA Label Image

O (Image 28)

An instructional illustration showing a close-up of an injection pen with a blue cap being removed. An arrow points upward, indicating the direction to pull off the cap, for preparing the injection pen for use.*

FDA Label Image

Warning 5 (Image 29)

OZEMPIC 2.68 mg/mL injection solution for subcutaneous use in a 1.5 mL pre-filled pen. The packaging is primarily white with purple accents and includes the A-S Medication Solutions labeler name. The vial is visible inside the box.*

FDA Label Image

P (Image 30)

An instructional diagram showing a hand removing or twisting the cap from the top of a pen-style injection device, indicated by a blue arrow pointing upward and to the left. The image demonstrates the first step in preparing the injection device for use.*

FDA Label Image

Q (Image 31)

Illustration showing a step for using a medication vial, depicting an injection needle being inserted into the vial's rubber stopper. This image likely demonstrates preparation or extraction of medication from the vial.*

FDA Label Image

R (Image 32)

An instructional illustration depicting hands preparing an injection pen device, demonstrating how to attach or adjust a component of the pen for administering a subcutaneous injection. The image uses blue and white colors and includes a corner marked with the letter 'R'.*

FDA Label Image

S (Image 33)

An instructional diagram showing the connection of two components, likely a needle or cap being attached or detached from a pen device. The image uses arrows to indicate the direction of movement for proper assembly or disassembly.*

FDA Label Image

Warning 6 (Image 34)

OZEMPIC 2.68 mg/mL injection solution in a 1.5 mL pre-filled pen pack, labeled for subcutaneous use. The packaging displays the A-S Medication Solutions labeler name and the National Drug Code 50090-6051. The carton is primarily white and orange with black text.*

FDA Label Image

Warning 7 (Image 35)

OZEMPIC 2.68 mg/mL injection solution in a glass vial with a blue and transparent plastic cap. The label shows the product name, semaglutide as the active ingredient, dosage form as injection, and route as subcutaneous. The vial is labeled by A-S Medication Solutions.*

FDA Label Image

Qr1 (Image 36)

FDA Label Image

Bull 1 (Image 37)

FDA Label Image

Warning 8 (Image 38)

OZEMPIC injection, solution, 2.68 mg/mL, shown in a clear glass vial with a white and gradient orange cap. The vial label displays the product name OZEMPIC prominently in orange, the active ingredient semaglutide, concentration, and usage instructions including instructions for subcutaneous administration. The labeler is A-S Medication Solutions and the vial appears intended for single patient use.*

FDA Label Image

Device 2 (Image 39)

An instructional diagram of the OZEMPIC pen and NovoFine Plus needle components, showing parts such as the pen cap, pen window with expiration and lot number labels, dose counter, dose pointer, dose selector, and dose button. Also includes the outer and inner needle caps, needle, paper tab, flow check symbol, and dashed line guide for dose adjustment.*

FDA Label Image

Figure A (Image 40)

An instructional illustration showing hands preparing a pen injector device, likely for subcutaneous injection. The image focuses on the removal or placement of a pen cap, demonstrating proper handling steps for use with the medication.*

FDA Label Image

B (Image 41)

An instructional illustration showing a hand holding a subcutaneous injection pen, likely demonstrating the preparation or administration of an injection, relevant to the use of OZEMPIC (semaglutide) injection solution.*

FDA Label Image

C (Image 42)

An instructional illustration showing a hand holding a device while removing or inserting a component by pulling it off in the direction of an arrow pointing to the left. The image appears to demonstrate part of the preparation or use process for a subcutaneous injection device, likely related to OZEMPIC semaglutide injection.*

FDA Label Image

D (Image 43)

An instructional illustration showing the step of attaching or preparing a syringe for injection, likely related to subcutaneous injection use. The image depicts a hand holding a syringe and interacting with the needle cap or protective cover.*

FDA Label Image

E (Image 44)

An instructional illustration depicting a person preparing a subcutaneous injection. The image shows hands holding a syringe-like device and a pen injector, demonstrating the process of removing the cap or attaching the needle before injection. This is relevant for the administration of subcutaneous injection solutions such as OZEMPIC (semaglutide) 2.68 mg/mL.*

FDA Label Image

F (Image 45)

An instructional illustration demonstrating how to prepare a subcutaneous injection using a syringe and vial, showing the insertion of the needle into the vial to draw medication.*

FDA Label Image

Warning 9 (Image 46)

OZEMPIC 2.68 mg/mL injection solution in a 3 mL pre-filled pen. The label includes the generic name semaglutide and indicates it is for subcutaneous use. The packaging shows the labeler as A-S Medication Solutions with Product NDC 50090-6051.*

FDA Label Image

Dose 2 (Image 47)

OZEMPIC injection, solution 2.68 mg/mL label by A-S Medication Solutions. It is a subcutaneous injectable human prescription drug. The label includes the product name OZEMPIC prominently, the active ingredient semaglutide, and details such as dosage form and route of administration. The label features a red and white color scheme with clear font for legibility.*

FDA Label Image

G (Image 48)

Instructional diagram showing a finger pressing a button on a device labeled with the letter 'G'. A text box at the bottom indicates the flow check symbol is selected, illustrating part of the usage process for the Ozempic semaglutide injection pen device.*

FDA Label Image

H (Image 49)

An instructional illustration showing a hand holding a device with a cap, with an arrow pointing upward, suggesting the removal or lifting of the cap from the device. The image appears related to the use of an injection pen or similar medical device.*

FDA Label Image

Warning 10 (Image 50)

OZEMPIC 2.68 mg/mL injection solution for subcutaneous use displayed in a clear glass vial with a white cap and a label that includes the product name, strength, and manufacturer, A-S Medication Solutions.*

FDA Label Image

Dash 2 (Image 51)

OZEMPIC injection, solution, 2.68 mg/mL in a clear vial with a black cap labeled by A-S Medication Solutions. The vial contains a transparent liquid and features text indicating the product name and strength.*

FDA Label Image

I (Image 52)

An instructional diagram showing how to select a dosage on a pen injector. The image highlights the dialed line with example doses of 0.25 mg (selected) and 0.5 mg (not selected) to guide users in setting the injection dose for a medication.*

FDA Label Image

Warning 11 (Image 53)

The image shows a clear glass vial labeled OZEMPIC semaglutide injection, solution with a strength of 2.68 mg/mL. The vial has a metal crimped cap and a rubber stopper. The label includes the labeler name A-S Medication Solutions and the product NDC 50090-6051. The solution inside the vial is colorless.*

FDA Label Image

J (Image 54)

An instructional illustration showing a hand holding a semaglutide injection pen labeled OZEMPIC. The pen displays a dosage window with the example dose stopped at 0.25 mg, demonstrating how to select and administer the dose using the pen for subcutaneous injection.*

FDA Label Image

K (Image 55)

An instructional anatomical diagram showing the recommended subcutaneous injection sites for administering a solution injection. The diagram depicts the front and back views of a human torso and legs, highlighting areas such as the abdomen, thighs, and upper arm as injection sites.*

FDA Label Image

L (Image 56)

An instructional illustration showing a hand holding a pen-like injection device, positioned for subcutaneous injection into the skin with a downward arrow indicating the injection direction.*

FDA Label Image

M (Image 57)

An instructional diagram illustrating how to hold and operate a pen-style injection device for subcutaneous administration. It shows a hand grasping the device with the thumb positioned to press down on the injection button, demonstrating the proper technique for use.*

FDA Label Image

N (Image 58)

An instructional illustration showing a hand holding an injection pen with a speech bubble indicating to count slowly: 1-2-3-4-5-6. The image suggests a step in the usage or administration process for the product.*

FDA Label Image

O (Image 59)

An instructional illustration showing the upper part of an injection device or pen with a needle attached. An upward-pointing arrow indicates the needle is being pulled off or removed from the injection device, suggesting a step in preparing the pen for subcutaneous injection.*

FDA Label Image

Warning 12 (Image 60)

OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use, displayed in a clear glass vial with a gray rubber stopper and a blue flip-off cap. The vial label includes product name, strength, and manufacturer A-S Medication Solutions, with additional dosing and storage information partially visible.*

FDA Label Image

P (Image 61)

Instructional illustration showing how to remove the protective cap from a prefilled injection pen or syringe. The image depicts a hand pulling the cap upward and away from the device, indicating preparation of the injection for use.*

FDA Label Image

Q (Image 62)

An instructional illustration showing the action of attaching or pressing a cap with a downward arrow onto the top of a circular container or vial, indicating a step for use or assembly related to the product.*

FDA Label Image

R (Image 63)

An instructional illustration showing a person holding a pen-like device, demonstrating how to properly attach or prepare a needle for injection. The image focuses on hand placement and needle handling, relevant for injection administration guidance.*

FDA Label Image

S (Image 64)

An instructional diagram demonstrating how to attach a needle to a pen-style injection device, likely for the subcutaneous injection of Ozempic (semaglutide) solution. The arrows indicate the steps for connecting the needle to the device.*

FDA Label Image

Warning 13 (Image 65)

OZEMPIC 2.68 mg/mL injection solution in a subcutaneous injection pen by A-S Medication Solutions. The label includes the proprietary name OZEMPIC and generic name semaglutide, with dosage strength clearly displayed. The product NDC is 50090-6051.*

FDA Label Image

Warning 14 (Image 66)

The image shows a carton of OZEMPIC injection, solution 2.68 mg/mL by A-S Medication Solutions. The packaging is primarily white with blue and purple text and design elements, including the OZEMPIC logo prominently displayed. It indicates the product is for subcutaneous use.*

FDA Label Image

Qr2 (Image 67)

FDA Label Image

Bull 2 (Image 68)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.